Successful Combination Treatment of a Patient with Progressive Juvenile Localized Scleroderma (Morphea) Using Imatinib, Corticosteroids, and Methotrexate

We report a case of progressive juvenile localized scleroderma (JLS or morphea) treated with a combination of imatinib, corticosteroids, and methotrexate. This therapy halted the progressive skin thickening and the hand and finger joint deformity in the early stages of the disease. We conclude that imatinib used in addition to standard treatment with systemic corticosteroids and methotrexate may be of therapeutic benefit for individuals with JLS.

[1]  T. Arkachaisri,et al.  Methotrexate and Corticosteroids in the Treatment of Localized Scleroderma: A Standardized Prospective Longitudinal Single-center Study , 2012, The Journal of Rheumatology.

[2]  M. Cutrone,et al.  Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. , 2011, Arthritis and rheumatism.

[3]  T. Krieg,et al.  Imatinib treatment of generalized localized scleroderma (morphea). , 2010, Journal of the American Academy of Dermatology.

[4]  T. Medsger,et al.  Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. , 2010, Rheumatology.

[5]  T. Medsger,et al.  The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures , 2009, The Journal of Rheumatology.

[6]  A. Gottlieb,et al.  A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. , 2008, Journal of the American Academy of Dermatology.

[7]  K. Evangelou,et al.  Imatinib for the treatment of refractory, diffuse systemic sclerosis. , 2008, Rheumatology.

[8]  C. Wouters,et al.  Localized scleroderma in childhood is not just a skin disease. , 2005, Arthritis and rheumatism.

[9]  W. Su,et al.  Classification of morphea (localized scleroderma) , 1995, Mayo Clinic proceedings.

[10]  Oliver Distler,et al.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. , 2007, Arthritis and rheumatism.

[11]  R. Schachter,et al.  Localized scleroderma. , 1989, Current opinion in rheumatology.